Additionally, in a Sjögren’s syndrome mouse model, TGP improved disease outcomes by modulating the Th1/Th2 cytokine balance and reducing IFN-γ, IL-4, Fas, and FasL expression (49). Here, FAS is linked to Sjogren syndrome.